NEW YORK (Reuters Health) - Therapy with valacyclovir (Valtrex, GlaxoSmithKline), started within three months of infection with either herpes simplex virus type 1 (HSV-1) or HSV type 2 (HSV-2), ...
Please provide your email address to receive an email when new articles are posted on . CHICAGO — Valacyclovir can be beneficial for treating multiple episodes of keratitis or iritis in patients with ...
Low-dose suppressive valacyclovir treatment of herpes zoster ophthalmicus (HZO) did not show significant benefits at 12 months but showed treatment superiority at 18 months and a reduction in the ...
TORONTO -- The antiviral agent valacyclovir demonstrated no benefit in early Alzheimer's disease, the phase II VALAD trial showed. On the primary outcome of change in Alzheimer's Disease Assessment ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Significant treatment benefits seen at 18 months; in addition, risk for experiencing subsequent end points lower with valacyclovir. HealthDay News — One year of valacyclovir is beneficial for patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results